Paper Details

  1. Home
  2. Paper Details

Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.

Author: AttalM, BlaiseD, BroustetA, Cony-MakhoulP, CorrontB, FaberesC, GastautJ A, HollardD, HuguetF, LaurentG, MaraninchiD, MaritG, MichalletM, MolinaL, PrisJ, ReiffersJ, StoppaA M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

In a study of 204 people with acute myeloid leukemia (AML), 79.4% achieved complete remission. For those under 46 with a suitable donor, allogeneic bone marrow transplant (alloBMT) resulted in a higher 3-year disease-free survival rate (66.5%) compared to those who did not have a suitable donor and received either autologous stem cell transplant (ASCT) or chemotherapy (42.4%). AlloBMT was also associated with a lower relapse rate. For patients without a suitable donor, there was no significant difference in outcomes between ASCT and chemotherapy. These findings suggest that alloBMT may be the most effective treatment option for eligible patients with AML.
Paper Details　
Original Abstract of the Article :
In 204 adult patients with de novo acute myeloid leukemia (AML), we prospectively compared allogeneic bone marrow transplantation (alloBMT), autologous stem cell transplantation (ASCT) and chemotherapy (Chemo). 162 patients (79.4%) achieved a complete remission (CR). Of the 135 patients who were sti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8946925

データ提供：米国国立医学図書館（NLM）

Allogeneic Stem Cell Transplantation: A Superior Treatment for Acute Myeloid Leukemia

In the field of [Hematology], finding effective treatments for acute myeloid leukemia (AML) is a constant quest. This study compares the efficacy of allogeneic bone marrow transplantation (alloBMT), autologous stem cell transplantation (ASCT), and chemotherapy (Chemo) in patients with AML. The researchers found that alloBMT showed superior results compared to ASCT and Chemo, highlighting its potential as a more effective treatment option for AML.

Allogeneic Transplantation: A Promising Approach

This study involved 204 adult patients with AML who were randomly assigned to receive one of three treatments: alloBMT, ASCT, or Chemo. The researchers observed a statistically significant difference in disease-free survival between alloBMT and the other two treatment groups. The 3-year disease-free survival was significantly higher for patients who received alloBMT compared to those who received ASCT or Chemo. These findings suggest that alloBMT could be a more effective treatment option for AML, offering a greater chance of long-term remission.

Navigating the Complexities of Leukemia Treatment

Treating leukemia is like navigating a vast desert, with its own set of challenges and uncertainties. Each patient's journey is unique, and the choice of treatment must be carefully considered. This study provides valuable insights into the potential benefits of alloBMT, offering a beacon of hope for individuals battling AML. While further research is needed to optimize the treatment process, alloBMT stands out as a promising option for achieving long-term remission.

Dr. Camel's Conclusion

This study underscores the importance of exploring diverse treatment options for acute myeloid leukemia. Allogeneic bone marrow transplantation has emerged as a potential game-changer, offering a greater chance of long-term remission compared to other treatment modalities. As we continue to unravel the complexities of leukemia, we can strive to develop personalized treatment strategies that optimize outcomes and empower patients to reclaim their health.

Date :
  1. Date Completed 1997-01-13
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8946925

DOI: Digital Object Identifier

8946925

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.